By FieldPulse Editorial · March 24, 2026
Tags: Drug Pricing, Policy, Compliance
The FTC has proposed a settlement with CVS Caremark over alleged insulin price manipulation by its PBM unit, with projected savings of $7 billion over a decade. CVS is now the second of the Big 3 PBMs to face a regulatory deal.
Federal regulators moved Monday to settle with CVS Caremark over allegations that its pharmacy benefit management operations manipulated insulin prices to the detriment of patients, proposing a resolution that the FTC projects could generate $7 billion in savings over the next decade. CVS Caremark is now the second of the three dominant PBMs to face a formal settlement with the commission — following Express Scripts — as federal scrutiny of the pharmacy middlemen intensifies. The proposed deal still requires approval from the FTC chair before it becomes final. The FTC's case against the major